On April 29, 2025, Xencor, Inc. announced positive interim results from its first-in-human study of XmAb942. XmAb942 is a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for inflammatory bowel disease (IBD).
The interim results support XmAb942 as a high-potency antibody and indicate that an every 12-week subcutaneous dosing regimen is feasible during the maintenance treatment period. This dosing schedule offers a more convenient option for patients compared to first-generation anti-TL1A antibodies.
These positive data are a significant step forward for XmAb942, which is being developed for conditions such as ulcerative colitis and Crohn's disease. The findings will inform the design and progression of future clinical studies, including the planned Phase 2b XENITH-UC study.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.